The MDC spinout raised a series B round which will be used to boost its manufacturing capacity and advance its pipeline of candidates.
T-Knife, a Germany-based developer of T-cell receptor therapeutics spun out of Max Delbrück Center for Molecular Medicine (MDC), has raised $110m in a series B round led by investment and financial services group Fidelity Management & Research Company.
The round was filled out by sovereign wealth fund Qatar Investment Authority, Life Science Partners, Casdin Capital, Sixty Degree Capital, CaaS Capital, RA Capital Management, Versant Ventures and Andera Partners.
Founded in 2018, T-Knife develops T-cell receptor (TCR) therapies for the treatment of solid tumours.
The company uses a proprietary transgenic mouse platform that produces human TCRs able to mimic the properties of virus-specific TCRs, avoiding immunological tolerance to self tumour antigens.
T-Knife’s lead programme, TK-8001, targets gastrointestinal, pulmonary, gynaecological and urogenital solid tumours. The company plans to begin enrolling patients for its TK-8001 Phase 1/2 clinical study in the fourth quarter of 2021.
The funding will…
